Juxtapid Phase 3 Achieves in HoFH; Needham & Company Maintains Aegerion (AEGR) at 'Hold' Pending Better Visibility

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/21/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. SPCX
7. AVGO
8. HD
9. BJ
10. BABA

Go back to Juxtapid Phase 3 Achieves in HoFH; Needham & Company Maintains Aegerion (AEGR) at 'Hold' Pending Better Visibility

Aegerion's (AEGR) Lomitapide Phase 3 in Japanese HoFH Patients Met Primary Endpoint

May 26, 2015 7:20 AM EDT

Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced the primary endpoint was achieved in the Company's open-label, multicenter study to evaluate the efficacy and safety of lomitapide in nine Japanese patients with homozygous familial hypercholesterolemia (HoFH). The primary endpoint measured mean percent change in low-density lipoprotein cholesterol (LDL-C) at the maximum tolerated... More